Compare WETH & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WETH | CING |
|---|---|---|
| Founded | 1992 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.1M | 26.4M |
| IPO Year | N/A | 2021 |
| Metric | WETH | CING |
|---|---|---|
| Price | $1.68 | $4.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $31.33 |
| AVG Volume (30 Days) | 90.6K | ★ 122.1K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.55 | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $43,519,385.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.82 | ★ N/A |
| Revenue Growth | ★ 6.08 | N/A |
| 52 Week Low | $0.76 | $3.20 |
| 52 Week High | $3.68 | $6.01 |
| Indicator | WETH | CING |
|---|---|---|
| Relative Strength Index (RSI) | 37.09 | 59.77 |
| Support Level | $1.75 | $3.75 |
| Resistance Level | $2.04 | $4.02 |
| Average True Range (ATR) | 0.17 | 0.23 |
| MACD | -0.04 | 0.06 |
| Stochastic Oscillator | 4.26 | 71.30 |
Wetouch Technology Inc is a touch panel supplier focused on R&D, production, and sales of touch screen products. It offers touchscreens for a variety of applications, including GPS/car entertainment panels for the automotive industry, industrial human-machine interface, financial and banking terminals, point of sale, lottery and gaming machines, smart home, robots, and charging stations. The company sells touchscreen products both domestically in China and internationally. The company generates the majority of its revenue from the PRC, followed by the Republic of China and Korea.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.